Get the Stockscreener App
4.53
5.82%
-0.28
After Hours:
4.50
-0.03
-0.66%
Ataibeckley Inc stock is traded at $4.53, with a volume of 4.81M.
It is down -5.82% in the last 24 hours and up +9.42% over the past month.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
See More
Previous Close:
$4.81
Open:
$4.78
24h Volume:
4.81M
Relative Volume:
0.84
Market Cap:
$1.67B
Revenue:
$4.09M
Net Income/Loss:
$-660.15M
P/E Ratio:
-1.965
EPS:
-2.3053
Net Cash Flow:
$-117.10M
1W Performance:
+4.86%
1M Performance:
+9.42%
6M Performance:
+11.58%
1Y Performance:
+92.77%
1-Day Range:
$4.46
$4.78
1-Week Range:
$4.265
$5.00
52-Week Range:
$2.00
$6.75
Ataibeckley Inc Stock (ATAI) Company Profile
Name
Ataibeckley Inc
Sector
Industry
Phone
1 929 207 2670
Address
C/O ATAI LIFE SCIENCES US, INC., NEW YORK
Compare ATAI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATAI
Ataibeckley Inc
|
4.53 | 1.77B | 4.09M | -660.15M | -117.10M | -2.3053 |
VRTX
Vertex Pharmaceuticals Inc
|
428.34 | 107.89B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
618.95 | 63.21B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
813.14 | 49.89B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
292.58 | 38.20B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.99 | 32.17B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ataibeckley Inc Stock (ATAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | Deutsche Bank | Buy |
| Jan-20-26 | Initiated | Guggenheim | Buy |
| Oct-13-25 | Initiated | Needham | Buy |
| Jul-29-25 | Initiated | Oppenheimer | Outperform |
| Nov-18-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-03-24 | Upgrade | Maxim Group | Hold → Buy |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
| Nov-11-21 | Initiated | ROTH Capital | Buy |
| Oct-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-01-21 | Initiated | Jefferies | Buy |
| Jul-13-21 | Initiated | Berenberg | Buy |
| Jul-13-21 | Initiated | Canaccord Genuity | Buy |
| Jul-13-21 | Initiated | Cantor Fitzgerald | Buy |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-13-21 | Initiated | Credit Suisse | Outperform |
| Jul-13-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-08-21 | Initiated | Aegis Capital | Buy |
View All
Ataibeckley Inc Stock (ATAI) Latest News
Is AtaiBeckley (ATAI) Using BPL-003’s Phase 3 Launch to Redefine Its Risk‑Reward Profile? - simplywall.st
ATAI: BPL-003 enters phase III for depression, with top-line data expected in early 2029 - TradingView
ATAI: BPL-003 phase III for depression begins, with VLS-01 phase IIb results due Q4 2024 - TradingView
AtaiBeckley to discuss Phase 3 BPL-003 program at multiple June investor conferences - TradingView
AtaiBeckley (NASDAQ: ATAI) to present BPL-003 Phase 3 updates - Stock Titan
Jefferies reiterates atai Life Sciences stock rating on pipeline progress - Investing.com
AtaiBeckley Grant Program Links Mental Health Impact With Investor Considerations - Sahm
ATAI Q1 2026 Earnings: Narrower Loss Beats Estimates; Stock Edges HigherEarnings Weakness Phase - thelegaladvocate.com
AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations - Investing News Network
Small cap wrap: AtaiBeckley, Medicus Pharma, Bit Digital, American Resources, Nextech3D.ai… - Proactive financial news
AtaiBeckley launches mental health patient impact grant program - Proactive financial news
AtaiBeckley to present at multiple investor conferences in June 2026, highlighting its mental health drug pipeline. - Pluang
AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026 - Investing News Network
AtaiBeckley to participate in multiple June investor conferences - Proactive financial news
AtaiBeckley Inc. Cash Flow – HAM:B72 - TradingView
Total debt of AtaiBeckley Inc. – HAM:B72 - TradingView
AtaiBeckley Inc. Balance Sheet – HAM:B72 - TradingView
Return on assets % of AtaiBeckley Inc. – HAM:B72 - TradingView
AtaiBeckley Inc. Trade Ideas — HAM:B72 - TradingView
AtaiBeckley (ATAI) Reports Q1 Financial Results - Insider Monkey
AtaiBeckley Inc. (ATAI) Surges 5.87%: Testing Key Resistance LevelsDip Buy Trade - thelegaladvocate.com
10 Best Penny Stocks to Buy for Long Term - Insider Monkey
These stocks are today’s movers: Fermi, AST SpaceMobile, Intel, Marvell, USA Rare Earth, Ataibeckley, and more - MSN
AtaiBeckley Inc. (NASDAQ: ATAI): Advancing Psychedelic Mental Health Therapies with Clinical Momentum - Kalkine
How AtaiBeckley’s Wider Q1 Loss But Lower Per-Share Hit At AtaiBeckley (ATAI) Has Changed Its Investment Story - simplywall.st
Trump's psychedelic drug order boosts investor interest with promise of faster reviews - marketscreener.com
A Look At AtaiBeckley (ATAI) Valuation As Share Price Momentum And DCF Signal Differ - Yahoo Finance
AtaiBeckley (ATAI) Stock: Slides -1.11%, Support at $3.80 2026-05-15Value ETF - thelegaladvocate.com
Cybin stands out as the most undervalued psychedelic stock as Trump signs on faster PTSD research - MSN
Psychedelic: Compass Pathways, AtaiBeckley, GH Research report earnings - TipRanks
H.C. Wainwright Maintains AtaiBeckley(ATAI.US) With Buy Rating, Maintains Target Price $25 - Moomoo
ATAI Technical Analysis | Trend, Signals & Chart Patterns | ATAIBECKLEY INC (NASDAQ:ATAI) - ChartMill
TD Cowen Maintains AtaiBeckley(ATAI.US) With Buy Rating - Moomoo
AtaiBeckley clinical pipeline advances toward multiple late-stage data catalysts, Jefferies says - Yahoo! Finance Canada
CCORF Maintains AtaiBeckley(ATAI.US) With Buy Rating, Maintains Target Price $15 - Moomoo
ATAI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Needham Maintains AtaiBeckley(ATAI.US) With Buy Rating, Raises Target Price to $15 - Moomoo
Psychedelic stocks soar as Trump signs order to ease access - MSN
AtaiBeckley Inc. 1Q 2026: Revenue $954K, EPS $(0.08) — 10-Q Summary - TradingView
Q1 2026 loss rises at AtaiBeckley (Nasdaq: ATAI); cash and securities detailed - Stock Titan
Small cap wrap: AtaiBeckley, Standard Uranium, 374Water, Nextsource Materials… - Proactive financial news
AtaiBeckley Reports Q1 2026 Results, Initiates BPL-003 Phase 3 for Depression, Projects Cash Runway Into 2029 - Minichart
ATAI Beckley earnings beat by $0.02, revenue topped estimates - Investing.com
AtaiBeckley Q1 Net Loss Narrows, Revenue Declines - Moomoo
AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update - Investing News Network
AtaiBeckley targets Q2 start for Phase 3 depression trial as pipeline advances - Yahoo Finance
Earnings Flash (ATAI) AtaiBeckley Posts Q1 Net Loss $0.08 a Share, vs. FactSet Est of $0.10 Loss - marketscreener.com
AtaiBeckley (NASDAQ: ATAI) details Q1 2026 loss and $209.9M cash runway - Stock Titan
Earnings Flash (ATAI) AtaiBeckley Posts Q1 Net Loss $0.08 a Share, Vs. FactSet Est of $0.10 Loss - Moomoo
Earnings Flash (ATAI) AtaiBeckley Inc. Reports Q1 Revenue $954,000, vs. FactSet Est of $130,000 - marketscreener.com
Earnings Flash (ATAI) AtaiBeckley Inc. Reports Q1 Revenue $954,000, Vs. FactSet Est of $130,000 - Moomoo
Ataibeckley Inc Stock (ATAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ataibeckley Inc Stock (ATAI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Craig Kevin James | Chief Medical Officer |
Apr 20 '26 |
Sale |
5.00 |
42,579 |
212,895 |
8,437 |
1.59%
0.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):